New Managing Director Announced for MSD in the UK and Ireland – Ben Lucas to succeed David Peacock

Save Print

February 4, 2022 11:03 am +00:00

Media Contacts


New Managing Director Announced for MSD in the UK and IrelandBen Lucas to succeed David Peacock

LONDON, February 2022– MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)) announced today that Ben Lucas will succeed David Peacock as Managing Director of MSD UK and Ireland as of February 1st.

Ben Lucas joins the UK business from MSD in the Netherlands where he has held the position of Managing Director for the last three years.

Ben will bring a wealth of knowledge and experience to his new role in the UK. He started his career working with elite athletes as an exercise physiologist at the Institute of Sport, Newcastle before joining MSD in 1999 in his first role in pharmaceuticals and progressed through to sales and marketing roles. Ben was instrumental in building the MSD Oncology Franchise in the UK & Ireland, pioneering solutions to accelerate access to new innovative medicines for UK patients, commenting on his new role, Ben said:

            “I am delighted to have been appointed as MD of MSD in the UK and Ireland. MSD has a rich heritage of helping to save and improve the lives of patients and populations around the world. Our people and teams here in the UK play a critical role enabling this to happen through scientific innovation and ensuring that the patient remains at the heart of all that we do.

            “I feel privileged to be able to help build on MSD’s existing strong heritage and legacy – but know that we cannot solve for current and future healthcare challenges alone. I look forward to building on the existing strong partnerships and collaborations in the UK to ensure that those who need our medicines and vaccines in the UK have access to them.”

Ben is married, with five daughters. His interests (aside from parenting) include rugby, football, cycling, golf, most spectator sports and country walks.

David Peacock has been appointed President of MSD in Asia Pacific and will be based in Singapore.

About MSD

For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.  MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit and connect with us @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook.

GB-NON-05512 | Date of Preparation: January 2022